| abstract |
The present art provides aryl or heteroaryltriazolone derivatives or pharmaceutically acceptable salts thereof, a process for preparing them, a pharmaceutical composition containing them, and their use. Aryl or heteroaryltriazolone derivatives or pharmaceutically acceptable salts thereof exhibit selective inhibitory activity against VAP-1 and are therefore useful in the treatment and prevention of, for example, non-alcoholic hepatic steatoopathy (NASH). Can be applied to. According to another aspect of the art, methods of treatment are provided that include the step of administering an aryl or heteroaryltriazolone derivative. |